IV 
119TH CONGRESS 
1ST SESSION 
H. RES. 848 
Supporting the role of the United States in helping save the lives of children 
and protecting the health of people in low-income countries with vaccines 
and immunization through Gavi, the Vaccine Alliance (‘‘Gavi’’). 
IN THE HOUSE OF REPRESENTATIVES 
OCTOBER 31, 2025 
Mr. KEAN (for himself, Mr. AMO, Ms. SALAZAR, Mr. FITZPATRICK, and Mr. 
LAWLER) submitted the following resolution; which was referred to the 
Committee on Foreign Affairs 
RESOLUTION 
Supporting the role of the United States in helping save 
the lives of children and protecting the health of people 
in low-income countries with vaccines and immunization 
through Gavi, the Vaccine Alliance (‘‘Gavi’’). 
Whereas, prior to 2000, the distribution of and the resources 
for vaccines for children in the developing world were de-
clining, immunization rates were stagnant or decreasing, 
and nearly 10,000,000 children died each year before 
reaching their 5th birthday; 
Whereas, prior to 2000, it was common for new lifesaving 
vaccines to take up to 15 years to be introduced in the 
world’s most impoverished countries; 
VerDate Sep 11 2014 
01:07 Nov 04, 2025
Jkt 069200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6300
E:\BILLS\HR848.IH
HR848
kjohnson on DSK7ZCZBW3PROD with $$_JOB
•HRES 848 IH 
Whereas, access to routine immunization and vaccines pro-
tects children from deadly but preventable diseases and 
contributes to national economic growth and poverty re-
duction by ensuring people live longer, healthier, and 
more productive lives; 
Whereas, in 2000, the United States, the United Nations 
Children’s Fund (UNICEF), the World Health Organiza-
tion (WHO), the World Bank, government donors, lower- 
income country governments, foundations (including the 
Bill & Melinda Gates Foundation), the private sector (in-
cluding the vaccine industry), faith-based organizations, 
civil society, and other partners joined forces to create a 
public-private partnership now known as Gavi, the Vac-
cine Alliance, in order to expand access to new and 
underused vaccines and support the introduction and 
scaleup of these vaccines into routine immunization sys-
tems in the world’s most impoverished countries; 
Whereas, from 2000 through 2023, with support from the 
United States, and other donors and partners, Gavi has 
supported country-led vaccine initiatives in 78 countries 
to support the immunization of more than 1,100,000,000 
additional children and averted an estimated 18,800,000 
deaths in the world’s most impoverished countries; 
Whereas Gavi has been a major contributor in reducing the 
number of childhood deaths in lower-income countries 
due to vaccine-preventable disease by 70 percent since 
2000; 
Whereas country ownership and sustainability are at the core 
of the Gavi model, which requires Gavi-eligible countries 
to contribute to a portion of vaccine costs and directly in-
vest in immunizing children, and Gavi-supported coun-
VerDate Sep 11 2014 
01:07 Nov 04, 2025
Jkt 069200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6300
E:\BILLS\HR848.IH
HR848
kjohnson on DSK7ZCZBW3PROD with $$_JOB
•HRES 848 IH 
tries contributed more than $1,700,000,000 to immuniza-
tion campaigns between 2008 and 2023; 
Whereas 78 low-income countries currently provide co-financ-
ing for new and underused vaccines supported by Gavi, 
more than 19 countries have transitioned from Gavi sup-
port by the end of 2022, and an additional 10 countries 
may transition by 2040, moving toward fully funding 
their immunization programs; 
Whereas Gavi has transformed the market for vaccines by 
matching pooled demand from low-income countries with 
secure, predictable financing to make vaccines more af-
fordable and supply more reliable, reducing the price of 
the most common vaccines by 24 percent from 2015 to 
2020 and increasing the number of global vaccine manu-
facturers selling pre-qualified Gavi-supported vaccines to 
the world’s most impoverished countries from 5 in 2001 
to 19 in 2023; 
Whereas Gavi estimates that its market shaping efforts will 
result in savings of over $900,000,000 from 2021 to 
2025 and may encourage research and development of 
new vaccines; 
Whereas Gavi is poised to provide the most comprehensive 
package of support in the 2021 to 2025 period by financ-
ing and delivering 18 vaccines to the world’s most impov-
erished countries; 
Whereas Gavi is collaborating with the Global Polio Eradi-
cation Initiative on the final push to end polio, and ex-
panding the integration of the inactivated polio vaccine 
into routine immunization programs; 
Whereas Gavi has made significant progress in supporting 
the development and stockpiling of effective vaccines to 
VerDate Sep 11 2014 
01:07 Nov 04, 2025
Jkt 069200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6300
E:\BILLS\HR848.IH
HR848
kjohnson on DSK7ZCZBW3PROD with $$_JOB